| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = -$14,112,000 ) (Continued on the next page) |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | CoVPN 3006 - A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine | 005 | 16 | NIH | 3/21/2022 | $818,451 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | CoVPN 3006 - A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine | 007 | 16 | NIH | 3/29/2022 | $1,334,886 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | CoVPN 3006 - A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine | 010 | 16 | NIH | 5/27/2022 | $0 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | CoVPN 3006 - A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine | 010 | 16 | NIH | 5/27/2022 | $0 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | CoVPN 3006 - A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine | 006 | 16 | NIH | 3/28/2022 | $1,011,819 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | CoVPN 3006 - A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine | 002 | 16 | NIH | 12/1/2021 | $3,872,089 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R00CA218896 | Defining novel genetic dependencies in spliceosome mutant leukemia | 001 | 5 | NIH | 6/13/2022 | -$77,497 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R00CA218896 | Defining novel genetic dependencies in spliceosome mutant leukemia | 000 | 5 | NIH | 11/15/2021 | $249,000 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01CA076287 | Radioimmunotherapy Combinations for B-cell Malignancy | 001 | 21 | NIH | 5/24/2022 | $33,051 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01CA076287 | Radioimmunotherapy Combinations for B-cell Malignancy | 002 | 21 | NIH | 5/25/2022 | -$33,051 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01CA076287 | Radioimmunotherapy Combinations for B-cell Malignancy | 003 | 21 | NIH | 6/8/2022 | -$318,377 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01CA114536 | Novel synthetic receptors with improved antigen specificity and specificity for cancer therapy | 001 | 16 | NIH | 1/4/2022 | $454,730 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01CA114536 | Novel synthetic receptors with improved antigen specificity and specificity for cancer therapy | 003 | 16 | NIH | 4/20/2022 | $0 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01CA114536 | Novel synthetic receptors with improved antigen specificity and specificity for cancer therapy | 004 | 16 | NIH | 6/8/2022 | -$379,344 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01AI054423 | Genetic requirements of Helicobacter pylori infection | 000 | 17 | NIH | 2/4/2022 | $100,859 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01AI054423 | Genetic requirements of Helicobacter pylori infection | 001 | 17 | NIH | 5/27/2022 | $0 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01AR045203 | D4Z4 Coding Transcripts and FSHD | 000 | 22 | NIH | 12/15/2021 | $514,273 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | CoVPN 5002: SARS-CoV-2 Prevalence Study -Supplement Request | 000 | 16 | NIH | 11/30/2021 | $511,999 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | CoVPN 5002: SARS-CoV-2 Prevalence Study -Supplement Request | 002 | 16 | NIH | 2/28/2022 | $1,853,211 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01CA215134 | Integrating health informatics in a scalable stepped care self-management program for survivors after hematopoietic cell transplantation | 002 | 5 | NIH | 6/10/2022 | -$410,148 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01CA215134 | Integrating health informatics in a scalable stepped care self-management program for survivors after hematopoietic cell transplantation | 001 | 5 | NIH | 2/7/2022 | $0 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01CA215134 | Integrating health informatics in a scalable stepped care self-management program for survivors after hematopoietic cell transplantation | 000 | 5 | NIH | 12/10/2021 | $560,444 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | F31AI150163 | Evolutionary dynamics of antibody affinity maturation | 001 | 3 | NIH | 5/27/2022 | -$36,887 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | F31AI150163 | Evolutionary dynamics of antibody affinity maturation | 000 | 3 | NIH | 12/16/2021 | $43,475 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01CA205248 | Anti-CD38 targeted alpha emitter radioimmunotherapy to eliminate multiple myeloma | 001 | 4 | NIH | 5/31/2022 | -$322,503 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01CA205248 | Anti-CD38 targeted alpha emitter radioimmunotherapy to eliminate multiple myeloma | 000 | 4 | NIH | 1/10/2022 | $378,721 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01HL136135 | Multiplex base/prime editors for in vivo selection of modified HSPCs in hemoglobinopathy | 000 | 6 | NIH | 12/31/2021 | $706,559 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01AI141435 | Tissue Regulatory T Cells in Mucosal Infection | 001 | 4 | NIH | 5/27/2022 | -$542,192 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01AI141435 | Tissue Regulatory T Cells in Mucosal Infection | 000 | 4 | NIH | 10/19/2021 | $654,099 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | CoVPN 5002: SARS-CoV-2 Prevalence Study -Supplement Request | 000 | 16 | NIH | 11/30/2021 | $255,679 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | CoVPN 5002: SARS-CoV-2 Prevalence Study -Supplement Request | 000 | 16 | NIH | 11/30/2021 | $1,993,638 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | CoVPN 5002: SARS-CoV-2 Prevalence Study -Supplement Request | 000 | 16 | NIH | 11/30/2021 | $187,919 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | CoVPN 5002: SARS-CoV-2 Prevalence Study -Supplement Request | 003 | 16 | NIH | 5/27/2022 | $0 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | CoVPN 5002: SARS-CoV-2 Prevalence Study -Supplement Request | 003 | 16 | NIH | 5/27/2022 | $0 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | CoVPN 5002: SARS-CoV-2 Prevalence Study -Supplement Request | 003 | 16 | NIH | 5/27/2022 | $0 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | CoVPN 5002: SARS-CoV-2 Prevalence Study -Supplement Request | 003 | 16 | NIH | 5/27/2022 | $0 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 001 | 16 | NIH | 11/23/2021 | $100,000 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 001 | 16 | NIH | 11/23/2021 | $603,323 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 001 | 16 | NIH | 11/23/2021 | $5,540,839 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 005 | 16 | NIH | 3/18/2022 | $1,324,786 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 006 | 16 | NIH | 3/29/2022 | $586,880 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 008 | 16 | NIH | 5/23/2022 | -$1,856,516 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 013 | 16 | NIH | 6/3/2022 | -$100,000 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 013 | 16 | NIH | 6/3/2022 | $3,764,298 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 013 | 16 | NIH | 6/3/2022 | -$5,540,839 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 019 | 16 | NIH | 6/17/2022 | $100,000 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 019 | 16 | NIH | 6/17/2022 | -$3,764,298 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 007 | 16 | NIH | 3/30/2022 | $1,856,516 |
| | 2022 | 2022 | FRED HUTCHINSON CANCER RESEARCH CENTER | 1100 FAIRVIEW AVE N J6-300 | SEATTLE | WA | 98109-4433 | KING | USA | R01CA076287 | Radioimmunotherapy Combinations for B-cell Malignancy | 000 | 21 | NIH | 1/11/2022 | $371,817 |
|
